/
IMDX
$3.71-$0.79 (-17.56%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$147.3M
33M shares
52-week range
$2.33 – $8.51
22% from low
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Exchange
NASDAQ
CS
Change+$0.55
Insight Molecular Diagnostics Inc. Common Stock
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
www.imdxinc.com- Employees
- 58
- IPO / List date
- Dec 30, 2015
- HQ
- NASHVILLE, TN
Held by traders on TradeandTell
No one on the platform currently holds IMDX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 13,400 | $100.5K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IMDX yet.
